Peripheral Neuropathy: The Evidence-Based Supplement Protocol

← Back to articles

Peripheral neuropathy has many causes; in developed countries diabetes is the most common. The single most important intervention is finding and treating the underlying cause — tight glycemic control in diabetes, repleting documented B12 deficiency, stopping alcohol, treating thyroid or celiac disease. The American Diabetes Association position statement stresses that good glucose control prevents or slows neuropathy in type 1 and helps in type 2, while pain itself is managed with proven agents (gabapentinoids, SNRIs, tricyclics). Against that backdrop, a few supplements have real but mostly modest adjunctive evidence — and a couple that are widely sold have been shown not to help, or even to harm.

Alpha-lipoic acid (ALA) — 600 mg daily (moderate evidence, diabetic neuropathy)

Alpha-lipoic acid has the strongest supplement evidence here. In the SYDNEY 2 RCT (181 adults), oral ALA 600 mg/day for 5 weeks cut the Total Symptom Score by roughly 51% versus 32% on placebo, with a 62% responder rate at the 600 mg dose; higher doses added toxicity (nausea, vomiting) without added benefit, so 600 mg is the preferred dose. A 2022 systematic review and meta-analysis of randomized trials confirmed ALA reduces total symptom score and individual symptoms (stabbing pain, burning, paresthesia, numbness) in diabetic polyneuropathy by both oral and IV routes; an earlier pooled analysis of IV trials (≈1,258 patients) reached similar conclusions. Effects on objective nerve deficits are smaller and less consistent than effects on symptoms. Take on an empty stomach. See our ALA piece.

Benfotiamine — 300–600 mg daily (limited evidence)

Benfotiamine is a fat-soluble thiamine derivative with better tissue uptake than thiamine HCl. The BENDIP RCT (133–165 adults) found a higher-dose, longer-duration signal: the Neuropathy Symptom Score improved significantly in the per-protocol analysis (p=0.033), but only borderline in the intention-to-treat analysis (p=0.055), and the Total Symptom Score did not reach significance at 6 weeks. A Cochrane review of B-vitamins for peripheral neuropathy found one small trial showing improved vibration perception with oral benfotiamine, but concluded the overall B-vitamin evidence was insufficient to judge benefit or harm. Reasonable to trial, well tolerated, but do not over-promise.

Vitamin B12 — only if deficient (correct the cause, not a tonic)

True B12 deficiency causes a sensory-predominant neuropathy that responds to repletion — but B12 is a treatment for deficiency, not a general nerve supplement. Screen B12 (with methylmalonic acid if borderline) in adults on long-term metformin, on proton-pump inhibitors, or with risk factors (vegan diet, post-bariatric surgery, atrophic gastritis). Replete with hydroxocobalamin or high-dose oral B12. See the B12 form piece.

Acetyl-L-carnitine — weak and uncertain (insufficient evidence)

Older industry-funded RCTs reported that acetyl-L-carnitine improved pain and vibratory perception in diabetic neuropathy, but a 2019 Cochrane review of 4 trials (907 patients) graded the evidence as very low certainty: any pain benefit was seen only at doses above 1,500 mg/day, and at ≤1,500 mg/day it was no different from placebo. Two of the four trials were industry-funded. Treat ALCAR as possibly helpful at higher doses but unproven, not as an established therapy. See the ALCAR vs LCAR piece.

What doesn't work, or can harm

High-dose vitamin B6 is a cause of neuropathy, not a cure. Chronic intake above ~100 mg/day can produce a sensory neuropathy, so avoid "nerve-repair" megaformulas that stack B6 at high doses. Vitamin D should be repleted only to correct deficiency; the interventional evidence that it treats neuropathy symptoms is weak. In the chemotherapy setting, a large randomized trial found acetyl-L-carnitine actually increased taxane-induced neuropathy — a reminder that "natural" does not mean safe. Avoid kratom (dependence, contamination) and do not substitute supplements for gabapentinoid or SNRI therapy in moderate-to-severe pain.

How to run the protocol

Confirm the diagnosis and pattern (nerve-conduction studies where unclear) and identify the cause. Check HbA1c, B12 (± methylmalonic acid), folate, thyroid function, and vitamin D. Optimize the underlying disease first. A reasonable adjunctive trial is ALA 600 mg/day, plus benfotiamine 300 mg/day, plus B12 repletion if deficient — reassessed at about 12 weeks. Add proven analgesic pharmacotherapy for pain rather than relying on supplements alone. Persistent or atypical neuropathy warrants neurology referral. See the condition page.